RedChip Investor Webinar with Lantern Pharma (NASDAQ: LTRN)
Date & Time:
August 26, 2025 4:15 PM ET (US and Canada)
Lantern Pharma (NASDAQ: LTRN) is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to address billion-dollar challenges in oncology drug development. By harnessing the power of AI, together with insights from world-class scientific advisors and collaborators, Lantern has accelerated the advancement of its growing pipeline of drug candidates across multiple cancer indications, including both solid tumors and blood cancers, as well as an antibody-drug conjugate (ADC) program. On average, Lantern’s newly developed drug programs progress from initial AI insights to first-in-human clinical trials within 2–3 years at a cost of approximately $1.0–2.5 million per program.
This webinar has concluded.
You can now register to watch the archived recording.
Lantern Pharma (NASDAQ: LTRN) is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to address billion-dollar challenges in oncology drug development. By harnessing the power of AI, together with insights from world-class scientific advisors and collaborators, Lantern has accelerated the advancement of its growing pipeline of drug candidates across multiple cancer indications, including both solid tumors and blood cancers, as well as an antibody-drug conjugate (ADC) program. On average, Lantern’s newly developed drug programs progress from initial AI insights to first-in-human clinical trials within 2–3 years at a cost of approximately $1.0–2.5 million per program.
Lantern Pharma (NASDAQ: LTRN) is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. The company’s proprietary AI and machine learning (ML) platform, RADR®, leverages over 200 billion oncology-focused data points and a library of more than 200 advanced ML algorithms to address billion-dollar challenges in oncology drug development. By harnessing the power of AI, together with insights from world-class scientific advisors and collaborators, Lantern has accelerated the advancement of its growing pipeline of drug candidates across multiple cancer indications, including both solid tumors and blood cancers, as well as an antibody-drug conjugate (ADC) program. On average, Lantern’s newly developed drug programs progress from initial AI insights to first-in-human clinical trials within 2–3 years at a cost of approximately $1.0–2.5 million per program.
